Has stenting killed local drug delivery?

European Heart Journal

Volumn 19, Issue 5, 1998, Pages 689-692

  Gunn, J ^a   Cumberland, D C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; UROKINASE;

CORONARY ARTERY ATHEROSCLEROSIS; DRUG DELIVERY SYSTEM; HUMAN; PRIORITY JOURNAL; RESTENOSIS; SHORT SURVEY; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CATHETERS, INDWELLING; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CORONARY ARTERIOSCLEROSIS; HUMANS; STENTS; TREATMENT OUTCOME;

EID: 0032080730     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1997.0829     Document Type: Short Survey

References (35)

1. [1] Kutryk MJB, Camenzind E, de Groot MR et al. Antisense oligonucleotide therapy for the prevention of stent restenosis. The ITALICS trial. Thoraxcenter Third Drug Delivery Meeting Abstract Book 1997: 70.
2. [2] Serruys PW, De Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-95.
3. [3] Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331: 496-501.
4. [4] Serruys PW, Emanuelsson H, van der Giesson W et al. Heparin-coated Palmaz-Schatz stents in human coronary arteries: early outcome of the Benestent-II pilot study. Circulation 1996; 93: 412-22.
5. [5] Mintz GS, Kent KM, Satler LF et al. Dimorphic mechanisms of restenosis after DCA and stents: a serial intravascular ultrasound study. Circulation 1995; 92: I-546-7.
6. [6] Sirnes PA, Golf S, Myreng Y et al. Stenting in chronic coronary occlusion (SICCO): a multi-center, randomized, controlled study. J Am Coll Cardiol 1996; 27: 139A.
7. [7] Danchin N, Lablanche JM, Grollier G et al. Intracoronary stenting in patients with unstable angina. Results from the TASTE registry. Circulation 1996; 94: 1-687.
8. [8] The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994; 330: 1084-89.
9. [9] The EPILOG Investigators. Platelet glycoprotien GPIIbIIIa receptor blockade and low dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 366: 1689-96.
10. [10] McKay RG, Fram DB, Hirst JA et al Treatment of intra-coronary thrombus with local urokinase using a new site-specific drug delivery system: the Dispatch catheter. Cathet Cardiovasc Diagn 1994; 33: 181-88.
11. [11] Camenzind E, Kint PP, Di Mario C et al. Intracoronary heparin delivery in humans. Acute feasibility and long term results. Circulation 1995; 92: 2463-72.
12. [12] Gallo R, Padurean A, Fuster V et al. Acute response to injury: the role of thrombus. Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries. Thoraxcenter Third Drug Delivery Meeting Abstract Book 1997: 2.
13. [13] Michel JF, Azrin MA, Alberghini TV et al. Site-specific thrombolysis with Reopro. Circulation 1996; 941: 1-202.
14. [14] Crea P. New predictors of restenosis: which patient to treat. Thoraxcenter Third Drug Delivery Meeting Abstract Book 1997: 34.
15. [15] Gonschior P, Vogel-Wiens C, Pahl C et al. Anti-inflammatories: perivascular delivery of prednisolone with the needle injection catheter in an experimental restenosis model. Thoraxcenter Third Drug Delivery Meeting Abstract Book 1997: 40.
16. [16] Gonschior P, Pahl C, Huehns TY et al. Comparison of different local intravascular drug delivery catheter systems. Am Heart J 1995; 130: 1174-81.
17. [17] Shi Y, Fard A, Galeo A et al. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation 1994; 90: 944-51.
18. [18] Asahara T, Bauters C, Pastore C et al. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 1995; 91: 2793-2801.
19. [19] Lam JYT. Local intramural NO-donor infusion followed by transdermal delivery inhibits neointimal thickening after balloon injury in the porcine model. Thoraxcenter Third Drug Delivery Abstract Book 1997: 62.
20. [20] Gunn J, Holt CM, Francis SE et al. The effect of oligonucleotides to c-cmyb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty. Circ Res 1997; 80: 520-31.
21. [21] Mintz GS, Pichard AD, Kent KM et al. Endovascular stents reduce restenosis by eliminating geometric remodelling: a serial intravascular ultrasound study. J Am Coll Cardiol 1995; 25: 36A.
22. [22] Shi Y, Pieniek M, Fard A et al. Adventitial remodeling after coronary arterial injury. Circulation 1996; 93: 340-8.
23. [23] Shi Y, O'Brien JE, Fard A, Mannion JD et al. Adventitial myofibroblasts contribute to neointimal formation in injured porcine arteries. Circulation 1996; 94: 1655-64.
24. [24] Barath P, Popov A, Michiels R. Nipple balloon catheter. Semin Intervent Cardiol 1996; 1: 43.
25. [25] Hofling B, Huehns TY, Gonschior P. Needle injection catheter. Semin Intervent Cardiol 1996; 1: 44.
26. [26] Wilensky RL. Biostent. Thoraxcentre Third Drug Delivery Meeting Abstract book 1997; 70.
27. [27] Dean LS, Roubin GS. Bail-out stenting: case closed. Semin Intervent Cardiol 1996; 1: 275-81.
28. [28] van der Giesson WJ, Lincoff AM, Schwartz RS et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996; 94: 1690-7.
29. [29] De Scheerder I, Wilczek K, Van Dorpe J et al. Local angiopeptin delivery using coated stents reduces neointimal proliferation in overstretched porcine coronary arteries. J Invas Cardiol 1996; 8: 215-22.
30. [30] Lambert TL, Dev V, Rechavia E et al. Localized arterial wall drug delivery from a polymer-coated removable metallic stent. Circulation 1994; 90: 1003-11.
31. [31] Aggarwal RK, Ireland DC, Ezekowitz MD et al. Anti-thrombotic potential of polymer-coated stents eluting platelet glycoprotein IIbIIIa receptor antibody. Circulation 1996; 94: 3311-17.
32. [32] Biocompatible Ltd. Data on file 1996.
33. [33] Armstrong J, Holt CM, Stratford P et al. Phosphorylcholine stent coating as a method of local drug delivery: preliminary data from an ex vivo model. Heart 1997; 77: P47.
34. [34] Flugelman MY, Virmani R, Leon MMB et al. Genetically engineered endothelial cells remain adherent and viable after stent deployment and exposure to pulsatile flow. Circ Res 1992; 70: 348-54.
35. [35] Wiedermann JG, Marboe C, Amols H, Schwartz A et al. Intracoronary irradiation markedly reduces restenosis after balloon angioplasty in a porcine model. J Am Coll Cardiol 1994; 23: 1491-8.